Pyridox(am)ine-5-Phosphate Oxidase Deficiency Treatable Cause of Neonatal Epileptic Encephalopathy With Burst Suppression

Abstract

Pyridox(am)ine-5-phosphate oxidase deficiency is an autosomal recessive disorder of pyridoxine metabolism. Intractable neonatal epileptic encephalopathy is the classical presentation. Pyridoxal-5-phosphate or pyridoxine supplementation improves symptoms. We report a patient with myoclonic and tonic seizures at the age of 1 hour. Pyridoxal-5-phosphate was started on the first day of life and seizures stopped at the age of 3 days, but encephalopathy persisted for 4 weeks. She had normal neurodevelopmental outcome at the age of 12 months on pyridoxal-5-phosphate monotherapy. She had novel homozygous pathogenic frameshift mutation (c.448_451del;p.Pro150Argfs*27) in the PNPO gene. Long-lasting encephalopathy despite well-controlled clinical seizures does neither confirm nor exclude pyridox(am)ine-5-phosphate oxidase deficiency. Normal neurodevelopmental outcome of our patient emphasizes the importance of pyridoxal-5-phosphate treatment. Pyridox(am)ine-5-phosphate oxidase deficiency should be included in the differential diagnosis of Ohtahara syndrome and neonatal myoclonic encephalopathy as a treatable underlying cause. In addition, we reviewed the literature for pyridox(am)ine-5-phosphate oxidase deficiency and summarized herein all confirmed cases.

Keywords

pyridox(am)ine-5-phosphate oxidase pyridoxal-5-phosphate neonatal myoclonic encephalopathy neonatal epilepsy Ohtahara syndrome

Get full access to this article

View all access options for this article.

References

Mills

Surtees

Champion

. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 59-phosphate oxidase. Hum Mol Genet. 2005;14:1077–1086.

Kuo

Wang

. Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine. Pediatr Neurol. 2002;26:146–147.

Clayton

Surtees

DeVile

. Neonatal epileptic encephalopathy. Lancet. 2003;361:1614.

Hoffmann

Schmitt

Windfuhr

. Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis. 2007;30:96–99.

Bagci

Zschocke

Hoffmann

. Pyridoxal phosphate-dependent neonatal epileptic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2008;93:F151–F152.

Ruiz

García-Villoria

Ormazabal

. A new fatal case of pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency. Mol Genet Metab. 2008;93:216–218.

Veerapandiyan

Winchester

Gallentine

. Electroencephalographic and seizure manifestations of pyridoxal 5'-phosphate-dependent epilepsy. Epilepsy Behav. 2011;20:494–501.

Goyal

Fequiere

. Seizures with decreased levels of pyridoxal phosphate in cerebrospinal fluid. Pediatr Neurol. 2013;48:227–231.

Pearl

Hyland

Chiles

. Partial pyridoxine responsiveness in PNPO deficiency. JIMD Rep. 2013;9:139–142.

10.

Porri

Fluss

Plecko

Paschke

Korff

Kern

. Positive outcome following early diagnosis and treatment of pyridoxal-5'-phosphate oxidase deficiency: a case report. Neuropediatrics. 2014;45:64–68.

11.

Ware

Earl

Salomons

. Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment. Dev Med Child Neurol. 2014;56:498–502.

12.

Khayat

Korman

Frankel

. PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism. Mol Genet Metab. 2008;94:431–434.

13.

Mills

Camuzeaux

SSM

Footlitt

. Epilepsy due to PNPO mutations: genotype environment and treatment effect on presentation and outcome. Brain. 2014;137:1350–1360.

14.

Plecko

Paul

Mills

. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. 2014;82:1425–1433.

15.

Schmitt

Baumgartner

Mills

. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52:e133–e142.

16.

Ishioka

Sato

Nakamura

Ohkubo

Takeda

Kurioka

. In vivo modification of GABAA receptor with a high dose of pyridoxal phosphate induces tonic-clonic convulsion in immature mice. Neurochem Int. 1995;26:369–373.

17.

Hammen

Wagner

Berkhoff

Donati

. A paradoxical rise of neonatal seizures after treatment with vitamin B₆ . Eur J Paediatr Neurol. 1998;2:319–322.

18.

Choi

Churchich

Zaiden

Kwok

. Brain pyridoxine-5-phosphate oxidase: modulation of its catalytic activity by reaction with pyridoxal 5-phosphate and analogs. J Biol Chem. 1987;262:12013–12017.

19.

Mills

Struys

Jakobs

. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12:307–309.

20.

Ohtahara

Yamatogi

. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res. 2006;70:S58–S67.

21.

Clarke

Gill

Noronha

McKinlay

. Early infantile epileptic encephalopathy with suppression burst: Ohtahara syndrome. Dev Med Child Neurol. 1987;29:520–528.

22.

Beal

Cherian

Moshe

. Early-onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy. Pediatr Neurol. 2012;47:317–323.

23.

Brautigam

Hyland

Wevers

. Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic l-amino acid decarboxylase deficiency. Neuropediatrics. 2002;33:113–117.